Analysts Set Hologic, Inc. (NASDAQ:HOLX) PT at $89.91

Shares of Hologic, Inc. (NASDAQ:HOLX) have been given a consensus recommendation of “Moderate Buy” by the twelve research firms that are covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $89.91.

A number of equities analysts have weighed in on the stock. UBS Group increased their target price on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Evercore ISI raised their price objective on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a report on Tuesday, October 1st. JPMorgan Chase & Co. lifted their price objective on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Raymond James raised their price target on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Finally, Needham & Company LLC reissued a “buy” rating and set a $90.00 price objective on shares of Hologic in a report on Tuesday, October 15th.

Hologic Trading Up 0.1 %

NASDAQ:HOLX opened at $79.50 on Wednesday. Hologic has a 12 month low of $67.59 and a 12 month high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The firm’s 50 day moving average is $80.18 and its 200 day moving average is $78.47. The stock has a market capitalization of $18.47 billion, a PE ratio of 23.87, a price-to-earnings-growth ratio of 2.51 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.01. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business’s revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.89 earnings per share. Sell-side analysts expect that Hologic will post 4.28 earnings per share for the current year.

Institutional Investors Weigh In On Hologic

A number of institutional investors and hedge funds have recently bought and sold shares of HOLX. Innealta Capital LLC purchased a new stake in Hologic during the second quarter valued at about $25,000. Wolff Wiese Magana LLC purchased a new position in shares of Hologic during the 3rd quarter valued at about $25,000. Groupama Asset Managment lifted its position in Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 2,999 shares during the last quarter. iA Global Asset Management Inc. purchased a new stake in Hologic in the first quarter worth approximately $37,000. Finally, Sunbelt Securities Inc. bought a new position in Hologic during the second quarter valued at approximately $37,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.